- Home
- GNRC vs BBIO Comparison
GNRC vs BBIO Comparison
Compare GNRC & BBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GNRC | BBIO |
|---|---|---|
| Founded | 1959 | 2015 |
| Country | United States | United States |
| Employees | 9400 | N/A |
| Industry | Metal Fabrications | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.2B | 15.3B |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | GNRC | BBIO |
|---|---|---|
| Price | $199.92 | $69.42 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 17 | 24 |
| Target Price | ★ $197.44 | $83.00 |
| AVG Volume (30 Days) | 1.1M | ★ 2.8M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $502,076,000.00 |
| Revenue This Year | $17.48 | $88.86 |
| Revenue Next Year | $10.90 | $74.11 |
| P/E Ratio | $84.89 | ★ N/A |
| Revenue Growth | N/A | ★ 126.26 |
| 52 Week Low | $104.90 | $28.33 |
| 52 Week High | $241.09 | $84.94 |
Technical Indicators
Market Signals| Indicator | GNRC | BBIO |
|---|---|---|
| Relative Strength Index (RSI) | 44.67 | 49.17 |
| Support Level | $162.14 | $61.95 |
| Resistance Level | $203.25 | $79.56 |
| Average True Range (ATR) | 9.78 | 3.33 |
| MACD | -4.91 | 0.53 |
| Stochastic Oscillator | 11.46 | 50.86 |
Price Performance
Historical ComparisonAbout GNRC Generac Holdlings Inc.
Generac designs and manufactures power generation equipment serving residential, commercial, and industrial markets. It offers standby generators, portable generators, lighting, outdoor power equipment, and a suite of clean energy products. Sales generated in the United States account for the majority of total sales.
About BBIO BridgeBio Pharma Inc.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis), is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.